Thermo buys Dionex
Thermo Fisher Scientific is to acquire Dionex Corporation for approximately $2.1 billion.
Thermo Fisher Scientific is to acquire Dionex Corporation for approximately $2.1 billion. The transaction will bring together two complementary chromatography portfolios; combining Dionex’s ion and liquid chromatography systems and consumables with Thermo Fisher’s gas chromatography systems and consumables.
“The combination of Thermo Fisher and Dionex is extremely compelling from a technology, market and financial perspective,” said Marc N. Casper, president and CEO of Thermo Fisher. “It complements our strong presence in China, where we’ve established the headquarters for our global environmental instruments business and continue to build our commercial infrastructure to meet the needs of customers in growing water quality, consumer safety and life sciences markets.” According to the companies, Dionex currently generates more than 35% of its revenues in Asia Pacific and other emerging high-growth geographies. This deal, therefore, continues Thermo Fisher’s reported strategy of increasing its footprint in Asian markets, as well as other global markets, such as Brazil.
“We are pleased to be joining Thermo Fisher,” said Frank Witney, president and CEO of Dionex. “Thermo Fisher’s commitment to innovation will fuel our ongoing technology development, and their global manufacturing and commercial presence will significantly strengthen our ability to deliver quality products and services to our customers around the world.”
This story originally appeared in The Column. Click here to view that issue.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
Katelynn Perrault Uptmor Receives the 2025 LCGC Emerging Leader in Chromatography Award
Published: November 13th 2024 | Updated: November 13th 2024November 13, 2024 – LCGC International magazine has named Katelynn A. Perrault Uptmor, Assistant Professor of Chemistry at the College of William & Mary, the recipient of the 2025 Emerging Leader in Chromatography Award. This accolade, which highlights exceptional achievements by early-career scientists, celebrates Perrault Uptmor’s pioneering work in chromatography, particularly in the fields of forensic science, odor analysis, and complex volatile organic compounds (VOCs) research.
